, Volume 22, Issue 5, pp 330–332 | Cite as

Treatment of chronic replicative hepatitis B virus infection with short-term continuous infusion of foscarnet

  • R. Schvarcz
  • Ola Weiland
  • B. G. Hansson
  • J. -O. Lernestedt


Three patients with chronic replicative hepatitis B virus infection were treated for 7 days with a continuous intravenous infusion of foscarnet (trisodium phosphonoformate) after an initial bolus dose of 20 mg/kg body weight. Although the dose was calculated from a nomogram, approximately only half the intended plasma concentration (500 µM/l=150 µg/l) was achieved. The levels of s-ALAT, HBV-DNA and DNA-polymerase changed only marginally during the treatment and 24-week follow-up period. All three patients remained HBsAg and HBeAg positive during treatment and follow-up. There were no severe side-effects. We conclude that foscarnet treatment with the dose regimen given in this study had no or only a minor antiviral effect in patients with chronic replicative HBV infection. It remains to be explored if higher doses, longer treatment periods or the use of foscarnet in combination regimen are more effective.


Foscarnet Initial Bolus Dose Phosphonoformate Intended Plasma Foscarnet Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Foscarnet in Kurzzeit-Dauertropfinfusion zur Behandlung der chronischen Hepatitis B mit aktiver Virusreplikation


Foscarnet (Trisodium-Fosfonoformat) wurde sieben Tage lang als intravenöse Dauertropfinfusion nach initialem Bolus von 20 mg/kg KG bei drei Patienten mit chronischer Hepatitis B und aktiver Virusreplikation eingesetzt. Obwohl die Dosis nach einem Nomogramm berechnet wurde, lagen die erreichten Plasmakonzentrationen (500 µM/l=150 µg/l) um etwa die Hälfte unter den angestrebten Werten. Während der Behandlung und einer Beobachtungszeit von 24 Monaten traten nur marginale Änderungen der s-ALAT, HBV-DNA und DNA-Polymerase-Spiegel ein. Alle Patienten blieben während der Behandlung und Beobachtungszeit HBsAg und HBeAg positiv. Wir schließen aus diesen Beobachtungen, daß Foscarnet in der in dieser Studie verabreichten Dosis keinen oder nur einen geringen antiviralen Effekt bei Patienten mit chronischer, replizierender HBV-Infektion hatte. Es bleibt zu prüfen, ob höhere Dosen, längere Behandlungsphasen oder die Anwendung von Foscarnet in Kombinationstherapie wirksamer sind.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hoofnagle, J. Alpha-interferon therapy of chronic hepatitis B. Current status and recommendations. J. Hepatol. (Suppl.) 11 (1990) 100–107.Google Scholar
  2. 2.
    Öberg, B. Antiviral effects of phosphonoformate. Pharmacol. Ther. 19 (1983) 387–415.Google Scholar
  3. 3.
    Löfgren, B., Nordenfeldt, E., Öberg, B. Inhibition of RNA- and DNA-dependent duck hepatitis B virus DNA polymerase activity by nucleoside and pyrophosphate analogs. Antiviral Res. 12 (1989) 301–310.Google Scholar
  4. 4.
    Nordenfeldt, E., Widell, A., Hansson, B., Löfgren, B., Möller-Nielsen, C., Öberg, B. Noin vivo effect of trisodium phosphonoformate on woodchuck hepatitis virus production. Acta Path. Microbiol. Immunol. Scand. Sec. B 90 (1982) 449–451.Google Scholar
  5. 5.
    Sherker, A., Hirota, K., Omata, M., Okuda, K. Foscarnet decreases serum and liver duck hepatitis B virus DNA in chronically infected ducks. Gastroenterology 91 (1986) 818–824.Google Scholar
  6. 6.
    Hedin, G., Weiland, O., Ljunggren, K., Nordenfeldt, E., Hansson, B., Lernestedt, J., Öberg, B. Treatment with foscarnet of fulminant hepatitis B and fulminant hepatitis B and D coinfection. In:Zuckermann, A. J. (ed): Viral hepatitis and liver disease. Alan R. Liss, Inc., New York 1988, pp. 947–952.Google Scholar
  7. 7.
    Bain, V., Daniels, H., Chanas, A., Alexander, G., Williams, R. Foscarnet therapy in chronic hepatitis B virus e antigen carriers. J. Med. Virol. 29 (1989) 152–155.Google Scholar
  8. 8.
    Antinori, S., Esposito, R., d'Aminio Monforte, A., Moroni, M. Foscarnet treatment of chronic hepatitis B in an HIV-positive patient. J. Hepatol. 18 (1993) 255–256.Google Scholar
  9. 9.
    Zhang, Y., Hansson, B., Kuo, L., Widell, A., Nordenfeldt, E. Hepatitis B virus DNA in serum and liver is commonly found in Chinese patients with chronic liver disease despite the presence of antibodies to HBsAg. Hepatology 17 (1993) 538–544.Google Scholar
  10. 10.
    Nordenfeldt, E., Öberg, B., Helgestrand, E., Miller, E. Inhibition of hepatitis B Dane particle DNA polymerase activity by pyrophosphate analogs. Acta Path. Microbiol. Immunol. Scand. Sect. B 88 (1980) 169–175.Google Scholar
  11. 11.
    Pettersson, K., Nordgren, T., Westerlund, D. Determination of phosphonoformate (foscarnet) on biological fluids by ion-pair reversed-phase liquid chromatography. J. Chromatog. 488 (1989) 447–455.Google Scholar
  12. 12.
    Nordenfeldt, E., Löfgren, B., Zhang, Y.: Treatment of duck hepatitis B virus infected ducks with combination of ganciclovir and foscarnet. Abstract, ISVHLD Tokyo (1993) p. 155.Google Scholar
  13. 13.
    Hansson, B., Riesbeck, K., Nordenfeldt, E., Weiland, O. Successful treatment of fulminant hepatitis B and fulminant hepatitis B and D coinfection explained by inhibitory effect on the immune response. In:Gerin, J., Rizetto, M., Purcell, B. (eds): The hepatitis delta virus. Alan R. Liss, Inc. New York 1990, pp. 421–427.Google Scholar

Copyright information

© MMV Medizin Verlag GmbH München 1994

Authors and Affiliations

  • R. Schvarcz
    • 1
  • Ola Weiland
    • 1
  • B. G. Hansson
    • 2
  • J. -O. Lernestedt
    • 3
  1. 1.Dept. of Infectious Diseases, Karolinska Institute I 73Huddinge HospitalHuddinge
  2. 2.Dept. of Medical Microbiology, Section of Clinical VirologyUniversity of Lund, Malmö General HospitalSweden
  3. 3.Astra Arcus ABSödertäljeSweden

Personalised recommendations